Cure Today10h
Opdivo with Abraxane May Expand Therapeutic Opportunities For MIBC
Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.
MedPage Today15h
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer
BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...
The American Journal of Managed Care16h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Cancer Therapy Advisor17h
Opdivo Approved in Neoadjuvant and Adjuvant Setting for Resectable NSCLC
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
pharmaphorum20h
FDA approval give BMS an edge in NSCLC treatment
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...
The Pharma Letter21h
FDA approves Opdivo for lung cancer before and after surgery
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...